DylanLauriSteenMD

PubMed

• 38 citations
  Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research.
  Ann Marie Navar, Eric D. Peterson, Dylan L. Steen, Daniel Wojdyla, Robert J. Sanchez
  JAMA Cardiology. 2019-04-01
• 160 citations
  A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
  Rishi K. Wadhera, Dylan L. Steen, Irfan Khan, Robert P. Giugliano, JoAnne M. Foody
  Journal of Clinical Lipidology. 2016-05-01
• 33 citations
  Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clin...
  Brian A. Bergmark, Jacob A. Udell, David A. Morrow, Christopher P. Cannon, Dylan L. Steen
  JAMA Cardiology. 2018-06-01

Journal Articles

• The Effect of Fasting Status on Lipids, Lipoproteins, and Inflammatory Biomarkers Assessed After Hospitalization for an Acute Coronary Syndrome: Insights from PROVE IT...  
  Dylan L Steen, Naseer Khan, Clinical Cardiology
• Widening the Path and Window of Opportunity for FDA Approval of Non-Vitamin K Oral Anticoagulant Specific Antidotes and Reversal Agents  
  Patel S, Steen DL, Journal of Thrombosis and Thrombolysis, 1/15/2015
• Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome: The SOLID-TIMI 52 Randomized Clinical Trial  
  O'Donoghue ML, Braunwald E, White HD, Steen DL, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wivio..., JAMA, 1/31/2014
• Prognostic evaluation of catalytic iron in patients with acute coronary syndromes: observations from OPUS-TIMI 16  
  Steen DL, Cannon CP, Lele SS, Rajapurkar MM, Mukhopadhyay B, Scirica BM, Murphy SA, Morrow DA, Clinical Cardiology, 1/1/2013
• Anacetrapib: Potential for the prevention and treatment of coronary heart disease  
  Steen DL, Khera AV, Cannon CP, Research Reports in Clinical Cardiology, 1/1/2013
• Statin potency associated with incident diabetes in a real-world evaluation  
  Steen DL, Bhatt DL, Evidence Based Med, 1/1/2013
• Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events Cardiology and Therapy  
  Steen DL, O’Donoghue ML, Cardiology and Therapy, 1/1/2013
• Prevalence of conduction abnormalities in a systolic heart failure population by race ethnicity, and gender  
  Hebert K, Quevedo HC, Tamariz L, Dias A, Steen DL, Colombo RA, Franco E, Neistein S, Arcement LM, Annals of Noninvasive Electrocardiography, 1/1/2012
• Atherosclerosis: Effects of evacetrapib administered as monotherapy or in combination with statins  
  Steen DL, Cannon CP, Reviews in Cardiovascular Medicine, 1/1/2012
• Open access to an outpatient intravenous diuresis program in a systolic heart failure disease management program  
  Hebert K, Dias A, Franco E, Tamariz L, Steen D, Arcement LM, Congestive Heart Failure, 1/1/2011
• Prevalence of electrocardiographic abnormalities in a systolic heart failure disease management population by race, ethnicity, and gender  
  Hebert K, Lopez B, Dias A, Steen DL, Colombo RA, Franco E, Neistein S, Arcement LM, Congestive Heart Failure, 1/1/2010
• Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population  
  Hebert K, Dias A, Delgado MC, Franco E, Tamariz L, Steen D, Trahan P, Major B, Arcement LM, European Journal of Heart Failure, 1/1/2010
• Join now to see all

Abstracts/Posters

• Prognostic Utility of Fibroblast Growth Factor-23 after an Acute Coronary Syndrome
  Udell JA, Morrow DA, Braunwald E, Cannon CP, Steen DL, Jarolim P, Lukas MA, Budaj A, Hamm C, Zhou J, Im K, Sabatine MS, O’Donoghue ML, ACC, 1/1/2015
• Galectin-3 for Heart Failure Risk Stratification in Patients After ACS: Insights from the SOLID-TIMI 52 trial
  Magnani G, O’Donoghue ML, Braunwald E, Steen DL, Jarolim P, Lukas MA, White HD, Lewis B, de Winter RJ, Zhou J, Im K, Cannon CP, Morrow DA, AHA, 1/1/2015
• Performance Reports and the Utilization of Guideline-Based Therapies in a Large Clinical Trial Population Enrolled after an Acute Coronary Syndrome: Insights from the...
  Steen DL, Cannon CP, Daga S, Lukas MA, Ophuis TO, Gratsiansky N, Crugnale S, Shannon J, O’Donoghue ML, ACC, 1/1/2015
• CV Event Rates in a High-Risk Managed Care Population in the United States
  Steen DL, Khan I, Song X, Sanchez R, Gorcyca K, Hollenbeak CS, Foody J, ACC, 1/1/2015
• Attainment of Secondary Lipid Targets in Patients at High Cardiovascular Risk: Results from a U.S. Managed Care Population Study
  Steen DL, Khan I, Becker L, Prairie E, Gorcyza K, Foody J, AHA, 1/1/2014
• Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Cardiovascular Risk: Results from a Managed Care Population Study
  Foody J, Steen DL, Khan I, Becker L, Gorcyca K, Lewis B, AHA Heart Association Scientific Sessions, 1/1/2013
• Utilization of Intensive Lipid-Lowering Therapy after an Acute Coronary Syndrome: Insights from the Triton-TIMI 38 Trial
  Steen DL, Umez-Eronini AA, Hoffman EB, Antman EM, Wiviott SD, AHA Heart Association Scientific Sessions, 1/1/2013
• Prognostic evaluation of catalytic iron in patients with acute coronary syndromes: observations from OPUS-TIMI 16
  Steen DL, Scirica BM, Murphy SA, Cannon CP, Morrow DA, American Heart Association Scientific Sessions, 1/1/2012
• Join now to see all

Other

• The Revised ACC/AHA/HRS Guidelines for the Management of Patients With Atrial Fibrillation 
  Steen DL
  1/25/2014
• A Middle-Aged Man With AFib and Mechanical Heart Valve 
  Steen DL
  1/15/2013
• HDL and CETP Inhibition 
  Steen DL, Wiviott SD, Cannon CP
  http://www.cardiosource.org/Science-And-Quality/Expert-Opinions-and-Cases/Hot-Topics/2012/02/HDL-and-CETP-Inhibition.aspx
  1/17/2012